- Conditions
- Generalized Myasthenia Gravis
- Interventions
- Inebilizumab
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 4
- States / cities
- Chicago, Illinois • Philadelphia, Pennsylvania • Austin, Texas + 1 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2713–2736
of 11,437
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Chronic Plaque Psoriasis
- Interventions
- Not listed
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 6,065 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2023
- U.S. locations
- 222
- States / cities
- Birmingham, Alabama • Daphne, Alabama • Huntsville, Alabama + 173 more
- Conditions
- Aortic Aneurysm
- Interventions
- Endovascular Repair, Standard Open Repair
- Procedure
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 50 Years and older
- Enrollment
- 881 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2012
- U.S. locations
- 42
- States / cities
- Birmingham, Alabama • Tucson, Arizona • No. Little Rock, Arkansas + 39 more
- Conditions
- Arthroplasty Shoulder, Periprosthetic Joint Infection
- Interventions
- Chlorhexidine Gluconate
- Drug
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years to 89 Years · Male only
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Fetal Monitoring
- Interventions
- Holter Device
- Device
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years to 55 Years · Female only
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2026
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Progressive Familial Intrahepatic Cholestasis, Alagille Syndrome, Cholestatic Liver Disease
- Interventions
- Maralixibat
- Drug
- Lead sponsor
- Mirum Pharmaceuticals, Inc.
- Industry
- Eligibility
- 0 Days to 364 Days
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 7
- States / cities
- Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 4 more
- Conditions
- Critical Limb Ischemia
- Interventions
- Open surgical revascularization, Endovascular revascularization
- Procedure · Device
- Lead sponsor
- Carelon Research
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,843 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2022
- U.S. locations
- 144
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 102 more
- Conditions
- Generalized Anxiety Disorder
- Interventions
- Placebo, DT120
- Other · Drug
- Lead sponsor
- Definium Therapeutics US, Inc.
- Industry
- Eligibility
- 18 Years to 74 Years
- Enrollment
- 214 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 34
- States / cities
- Gilbert, Arizona • Scottsdale, Arizona • La Jolla, California + 27 more
- Conditions
- Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
- Interventions
- NX-5948
- Drug
- Lead sponsor
- Nurix Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 32
- States / cities
- Phoenix, Arizona • Duarte, California • Irvine, California + 29 more
- Conditions
- Lymphoma
- Interventions
- rituximab, cyclophosphamide, doxorubicin hydrochloride, prednisone, vincristine sulfate, R-CHOP regimen, laboratory biomarker analysis, fludeoxyglucose F 18, selective external radiation therapy, yttrium Y 90 ibritumomab tiuxetan
- Biological · Drug · Other + 1 more
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 159 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2023
- U.S. locations
- 240
- States / cities
- Anchorage, Alaska • Tucson, Arizona • Aurora, Colorado + 153 more
- Conditions
- Obesity
- Interventions
- CP-945,598, Non-pharmacological weight loss program (NPP), Low Calorie Diet
- Drug · Behavioral
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 699 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 9
- States / cities
- La Jolla, California • Denver, Colorado • Baton Rouge, Louisiana + 6 more
- Conditions
- Hearing Loss
- Interventions
- Group hearing aid fittings, Group hearing aid follow-up
- Procedure
- Lead sponsor
- US Department of Veterans Affairs
- Federal
- Eligibility
- Not listed
- Enrollment
- 660 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Nonarteritic Anterior Ischemic Optic Neuropathy
- Interventions
- PDE5 Inhibitors
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 345 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 44
- States / cities
- Birmingham, Alabama • Los Altos, California • National City, California + 40 more
- Conditions
- Advanced Dedifferentiated Liposarcoma, Locally Advanced Dedifferentiated Liposarcoma, Metastatic Dedifferentiated Liposarcoma, Stage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Stage IV Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Unresectable Dedifferentiated Liposarcoma
- Interventions
- Palbociclib, Cemiplimab, Magnetic Resonance Imaging, Computed Tomography, Biospecimen collection, Questionnaire Administration
- Drug · Biological · Procedure + 1 more
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 194
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 146 more
- Conditions
- Mandibular Fractures
- Interventions
- Surgery, Non-Surgical fracture treatment
- Procedure · Other
- Lead sponsor
- AO Clinical Investigation and Publishing Documentation
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 25 participants
- Timeline
- 2019 – 2023
- U.S. locations
- 3
- States / cities
- Sacramento, California • Baltimore, Maryland • Seattle, Washington
- Conditions
- Brain Concussion
- Interventions
- M-STEP
- Behavioral
- Lead sponsor
- Seattle Children's Hospital
- Other
- Eligibility
- 9 Years to 25 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Prolonged Air Leak
- Interventions
- Treatment with HUD IBV Valve System
- Device
- Lead sponsor
- Olympus Corporation of the Americas
- Industry
- Eligibility
- Not listed
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2017
- U.S. locations
- 13
- States / cities
- Atlanta, Georgia • Chicago, Illinois • Springfield, Illinois + 9 more
- Conditions
- Other Cancer
- Interventions
- ruxolitinib
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 7
- States / cities
- Duarte, California • Tampa, Florida • Boston, Massachusetts + 4 more
- Conditions
- Central Nervous System Tumor, Pediatric, Glioma, Ependymoma, Medulloblastoma, Germ Cell Tumor, Atypical Teratoid/Rhabdoid Tumor, Primitive Neuroectodermal Tumor, Choroid Plexus Carcinoma, Pineoblastoma
- Interventions
- EGFR806-specific chimeric antigen receptor (CAR) T cell
- Biological
- Lead sponsor
- Seattle Children's Hospital
- Other
- Eligibility
- 1 Year to 26 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Anemia
- Interventions
- Ferrlecit (sodium ferric gluconate complex in sucrose injection)
- Drug
- Lead sponsor
- Watson Pharmaceuticals
- Industry
- Eligibility
- 2 Years to 16 Years
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2003
- U.S. locations
- 8
- States / cities
- Birmingham, Alabama • Los Angeles, California • San Diego, California + 5 more
- Conditions
- Unspecified Childhood Solid Tumor, Protocol Specific
- Interventions
- ECTEINASCIDIN 743
- Drug
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 1 Year to 17 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2005
- U.S. locations
- 42
- States / cities
- Little Rock, Arkansas • La Jolla, California • Los Angeles, California + 34 more
- Conditions
- Myasthenia Gravis, Generalized
- Interventions
- zilucoplan (RA101495), Placebo
- Drug
- Lead sponsor
- Ra Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 74 Years
- Enrollment
- 174 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 37
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Los Angeles, California + 33 more
- Conditions
- Pancreatic Ductal Adenocarcinoma, Non Small Cell Lung Cancer, Colorectal Cancer, Solid Tumor, Adult, G12D Mutated KRAS
- Interventions
- VS-7375, Cetuximab, Carboplatin + Pemetrexed + Pembrolizumab, Gemcitabine + Nab-paclitaxel, Pembrolizumab, Defactinib, Midazolam, Repaglinide
- Drug
- Lead sponsor
- Verastem, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 616 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 13
- States / cities
- Los Angeles, California • Baltimore, Maryland • Boston, Massachusetts + 10 more
- Conditions
- Pulmonary Hypertension, Interstitial Lung Disease, Combined Pulmonary Fibrosis and Emphysema
- Interventions
- Inhaled Treprostinil, Placebo
- Drug
- Lead sponsor
- United Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 326 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 96
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 71 more